Ultrashort-acting β-blockers lower mortality in patients with septic shock: Study

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-06-16 03:30 GMT   |   Update On 2023-10-10 12:04 GMT

Japan: The use of ultrashort-acting β-blockers (such as esmolol and landiolol) significantly lowered 28-day mortality in sepsis patients with persistent tachycardia despite initial resuscitation, finds a recent study in the journal Chest.Historically, the use of β-blockers is relatively contraindicated for a septic shock as they may lead to cardiac suppression. On the other hand, there is...

Login or Register to read the full article

Japan: The use of ultrashort-acting β-blockers (such as esmolol and landiolol) significantly lowered 28-day mortality in sepsis patients with persistent tachycardia despite initial resuscitation, finds a recent study in the journal Chest.

Historically, the use of β-blockers is relatively contraindicated for a septic shock as they may lead to cardiac suppression. On the other hand, there is an increasing interest in the β-blockers use for the treatment of patients with sepsis with persistent tachycardia despite initial resuscitation.

Osamu Nishida, Fujita Health University School of Medicine, Aichi, Japan, and colleagues, therefore, aimed to determine whether ultrashort-acting β-blockers such as esmolol and landiolol improve mortality in patients with sepsis with persistent tachycardia despite initial resuscitation in a systematic review and meta-analysis

For this purpose, the researchers searched the online databases for randomized controlled trials (RCTs) that compared the mortality of patients with sepsis and septic shock treated with esmolol or landiolol. Seven RCTs with a pooled sample size of 613 patients were included. Of these, six RCTs with 572 patients reported 28-day mortality. 

Key findings of the study include:

  • Esmolol or landiolol use in patients with sepsis and septic shock was significantly associated with lower 28-day mortality (risk ratio, 0.68).
  • Unimportant heterogeneity was observed (I2 = 31%).
  • The absolute risk reduction and number of patients to be treated to prevent one death were 18.2% and 5.5, respectively.

"Our findings show that the use of ultrashort-acting β-blockers such as esmolol and landiolol in patients with sepsis with persistent tachycardia despite initial resuscitation was associated with significantly lower 28-day mortality," concluded the authors. 

Reference:

The study titled, "Effect of Ultrashort-Acting β-Blockers on Mortality in Patients With Sepsis With Persistent Tachycardia Despite Initial Resuscitation: A Systematic Review and Meta-analysis of Randomized Controlled Trial," is published in the journal Chest.

DOI: https://journal.chestnet.org/article/S0012-3692(21)00035-0/fulltext

Tags:    
Article Source : journal Chest

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News